Welcome to our dedicated page for ZyVersa Therapeutics news (Ticker: ZVSA), a resource for investors and traders seeking the latest updates and insights on ZyVersa Therapeutics stock.
ZyVersa Therapeutics Inc (Nasdaq: ZVSA) is a clinical-stage biopharmaceutical company pioneering treatments for renal and inflammatory diseases through its Cholesterol Efflux Mediator and Inflammasome ASC Inhibitor platforms. This dedicated news hub provides investors and medical professionals with timely updates on clinical developments, regulatory milestones, and scientific advancements.
Access verified press releases and curated news about ZVSA's innovative pipeline, including progress on VAR 200 for kidney disorders and IC 100's multi-targeted approach to inflammation. Our collection spans essential updates like trial results, research partnerships, and peer-reviewed study publications, ensuring you stay informed about breakthroughs in high-need therapeutic areas.
This resource eliminates the need to track multiple sources by aggregating essential updates about ZyVersa's evidence-based drug development. Discover how the company addresses conditions like focal segmental glomerulosclerosis and metabolic complications through its unique 'pipeline within a product' strategy.
Bookmark this page for efficient tracking of ZVSA's progress in transforming treatment paradigms. Check regularly for new developments directly impacting the company's position in the biopharmaceutical sector.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced a public offering of 11,015,500 shares of common stock and warrants, priced at $1.00 per share, aiming for gross proceeds of approximately $11.0 million. The offering is expected to close around April 28, 2023, contingent on customary conditions. Proceeds will primarily be used for redeeming PIPE shares, covering offering expenses, and general corporate purposes. A.G.P./Alliance Global Partners is the lead placement agent, while The Benchmark Company acts as a co-placement agent. This offering follows their SEC registration statement effective on April 26, 2023.
On April 25, 2023, ZyVersa Therapeutics (Nasdaq: ZVSA) announced the publication of a research article in the Journal of Neuroinflammation highlighting ASC specks as a therapeutic target for Parkinson's disease (PD). The study's findings indicate a direct relationship between ASC protein levels and misfolded α-synuclein aggregates in PD models, suggesting that ASC specks contribute to the progression of PD pathology. Key results include enhanced NLRP3 inflammasome activation and accelerated degeneration of dopaminergic neurons linked to ASC specks. ZyVersa's proprietary monoclonal antibody, IC 100, aims to inhibit this inflammation and has demonstrated potential benefits in various CNS and inflammatory diseases. The company continues to advance its therapeutic pipeline focusing on innovative treatments for significant unmet medical needs.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) has appointed Dr. Douglas Golenbock to its Inflammatory Disease Scientific Advisory Board. Dr. Golenbock, a leading figure in innate immunity, brings extensive expertise with nearly 300 peer-reviewed publications and over 81,000 citations. His research focuses on inflammation mechanisms relevant to various diseases. ZyVersa is developing a specialized pipeline including Inflammasome ASC Inhibitor IC 100, a monoclonal antibody aimed at disrupting harmful inflammatory processes. Dr. Golenbock's involvement is expected to enhance ZyVersa’s clinical development efforts, particularly for treating renal and inflammatory disorders. The company aims to address significant unmet medical needs in these areas.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced the publication of a scientific paper in the journal Biomaterials, authored by researchers from the University of Miami, focusing on deep brain stimulation devices and their interactions with inflammasomes. Key findings indicated that:
- Continuous activation of inflammasomes leads to neuroinflammation at the microelectrode-tissue interface.
- Glial cell activation and upregulation of inflammasome sensor molecules were observed.
- Persistent neuroinflammation could contribute to device failure and neuronal cell loss.
The study supports the therapeutic potential of ZyVersa's Inflammasome ASC Inhibitor IC 100 in treating neurological disorders. The company is advancing multiple therapeutic programs aimed at addressing significant unmet medical needs in renal and inflammatory diseases.
ZyVersa Therapeutics (Nasdaq: ZVSA) has published a review article in Frontiers in Pharmacology discussing the NLRP3 inflammasome pathway as a potential target for treating mild cognitive impairment and Alzheimer’s disease. The paper outlines significant findings, including elevated IL-1β levels in Alzheimer's patients and positive results from anti-ASC antibody trials in animal models. The authors emphasize that treatments targeting the NLRP3 pathway may help reduce cognitive decline and Alzheimer's pathology. Co-founder Stephen C. Glover highlighted the urgent need for effective therapies to address cognitive impairment. ZyVersa is developing IC 100, a monoclonal antibody aimed at inhibiting this inflammasome pathway to mitigate inflammation-related damage in the central nervous system.
ZyVersa Therapeutics (Nasdaq: ZVSA) announced that CEO Stephen C. Glover will participate in a live interview on Benzinga All Access on April 18, 2023, at 11:10 AM EDT. The discussion will focus on the development progress of the company’s Cholesterol Efflux Mediator™ VAR 200 for renal disease and Inflammasome ASC Inhibitor IC 100 for CNS and non-CNS inflammatory diseases. Glover expressed enthusiasm for sharing ZyVersa's advancements in addressing unmet medical needs within its pipeline, particularly for kidney and inflammatory diseases. If you miss the live session, an archived version will be accessible online after the interview. For further details about ZyVersa and its proprietary technologies, visit their official website.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA), a biopharmaceutical company, has announced that CEO Stephen C. Glover will present at the Planet MicroCap Showcase 2023 in Las Vegas. The event is scheduled for April 26, 2023, at 2:00 PM PDT at Horseshoe Hotel & Casino. Glover will discuss the development of two key product candidates: Cholesterol Efflux Mediator™ VAR 200, aimed at addressing renal diseases, and Inflammasome ASC Inhibitor IC 100, targeting various CNS and inflammatory diseases. ZyVersa is focused on creating first-in-class therapies for unmet medical needs in renal and inflammatory diseases. Stakeholders are encouraged to schedule one-on-one meetings with Glover through the conference portal to learn more about the company’s innovative pipeline.
ZyVersa Therapeutics (NASDAQ: ZVSA) announced a significant scientific publication in the peer-reviewed journal Brain Pathology, focusing on the inflammasome ASC Inhibitor IC 100. This research, conducted by experts from the University of Miami, indicates that increased expression of inflammasome proteins like NLRP1 and NLRP3 occurs early in Alzheimer's disease (AD). The findings suggest that IC 100 could serve as a diagnostic tool and an early therapeutic intervention for AD by identifying neurons affected by the disease.
The study highlights the correlation between ASC expression and biomarkers of AD progression (Aβ and p-tau). ZyVersa's preclinical data indicate that IC 100 may alleviate chronic neuroinflammation, which plays a crucial role in AD progression.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced a significant corporate update, following its business combination with Larkspur Health Acquisition Corp. in December 2022. The company has initiated trading on Nasdaq and is advancing its lead clinical candidate, Cholesterol Efflux Mediator™ VAR 200, with an investigator-initiated trial planned for FSGS and other renal indications in Q4 2023. ZyVersa also prepares for an IND submission for inflammasome ASC inhibitor IC 100 in Q2 2024, supported by recent promising preclinical data. Despite not generating revenue since inception, the firm anticipates 2023 will be pivotal for growth.
ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA) announced the grant of inducement equity awards to two newly hired employees, effective March 8, 2023. The grants comprise nonqualified stock options to purchase a total of 13,000 shares at an exercise price of $2.26 per share, aligning with the closing price on that date. These options will vest in three annual installments starting March 8, 2024, contingent upon continued employment. ZyVersa focuses on developing first-in-class drugs for renal and inflammatory diseases, with products like VAR 200 targeting rare kidney diseases. The company emphasizes a commitment to addressing significant unmet medical needs.
FAQ
What is the current stock price of ZyVersa Therapeutics (ZVSA)?
What is the market cap of ZyVersa Therapeutics (ZVSA)?
